Tenn. lawmaker proposes bill that would require HIV testing among prison inmates prior to release

Tennessee state Rep. Brenda Gilmore (D) has introduced a bill (H.B. 52) that would require HIV tests for prison inmates before their release as part of a larger plan to address the spread of HIV/AIDS in the state, WSMV.com reports. According to Gilmore, the plan will focus on blacks, who comprise 64% of new HIV cases in the state but only 13% of the population.

According to Gilmore, the bill will allow former inmates to become more aware of HIV/AIDS issues and take precautionary measures, WSMV.com reports. She said that a recent report showed that many prison inmates return to prison within three years, adding that "this revolving door creates a culture" of HIV/AIDS that particularly affects black women. Last year, Gilmore proposed similar legislation to require HIV testing among inmates prior to release, and the bill passed in the House. However, the Senate did not take action on the bill. According to WSMV.com, Gilmore is waiting for a hearing on the current bill (Kumari, WSMV.com, 3/24).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New insights into the mechanisms of efavirenz-induced neurotoxicity